Table 3.

Summary of differences between parent B. pseudomallei and in vivo isolates in chemical sensitivities

Chemical	No. strains with: variant isolates/total no. strainsa	Increased in
		Sensitivity	Resistance
Niaproof 4	6/6	3b,c	5b,c
Nalidixic acid	5/6	1	5b
Mastoparan 7	4/6	1	4b
BMAP-18	3/4e	0	3
Minocycline	3/6	2	2b
Nitrite	3/6	2	1
NaCl	3/6	0	3
Potassium tellurite	3/6	1b	3b
Magainin	2/6	0	2
Melittin	2/6	1	1
d-Serine	2/6	1	1
Others	1/6d,e	–	–

^aSpleen isolates from aerosol or IP challenge experiments of seven Bp strains were obtained (17 total experiments). The variant responses of the isolates consisted of significant increases in either sensitivity (S) or resistance (R) to the antimicrobial chemical compared to the challenge strain, as described in the methods. The data do not include isolates exhibiting no differences from the parent. For strain HBPUB10134a, no isolates were obtained from survivor spleens cultured later than 14 days after challenge, so the data are not included in the table

^bThe sensitivity of isolates collected at early and later time points differed (nalidixic acid, potassium tellurite, Niaproof 4, and mastoparan 7) or individual isolates from a given challenge experiment collection responded differently, being either more sensitive or more resistant than the parent (minocycline, Niaproof 4, potassium tellurite, and mastoparan 7) as described in the text

^cDifferent responses by the same isolate were observed in Biolog and antimicrobial sensitivity microtiter assays, but chemical concentrations in the Biolog system are proprietary and unavailable

^dFor one Bp strain each, the sensitivity to the chemical of an isolate(s) varied from that of the parent as follows: aztreonam (R), guanidine HCl (R), LL-37 (R), CA-MA (R), and bactenecin (variable)

^ePeptides BMAP-18, CA-MA, bactenecin, and LL-37 were tested in four of the six strains only